FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 319:1374-1378 November 24, 1988 Number 21 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Neonatal alloimmune thrombocytopenia results from the formation of a maternal antibody to a paternal antigen on fetal platelets. Intracranial hemorrhage, which may be antenatal, occurs in approximately 15 to 20 percent of infants with this form of thrombocytopenia. In families with an affected infant, 75 percent of subsequent infants are affected. We report the results of antenatal treatment with intravenous gamma globulin, with or without dexamethasone, in seven pregnant women who had previously had infants who had severe alloimmune thrombocytopenia. The platelet count increased by a mean (+/- SD) of 72.5 +/- 62 x 10(9) per liter in the six fetuses in whom periumbilical blood sampling was performed. All seven treated fetuses had platelet counts above 30 x 10(9) at birth, and none had an intracranial hemorrhage, in contrast to all seven of their respective untreated siblings, who had lower platelet counts and three of whom had intracranial hemorrhages (antenatal in two infants). Mild intrauterine growth retardation was observed in one treated infant; all seven infants have developed normally in the two months to four years since birth. We conclude that intravenous gamma globulin, with or without dexamethasone, is effective in elevating the fetal platelet count in severe cases of neonatal alloimmune thrombocytopenia and in helping to avoid intracranial hemorrhage.

Source Information

Department of Pediatrics, Cornell University Medical Center, New York Hospital, NY 10021.

This article has been cited by other articles:

• Berkowitz, R. L., Lesser, M. L., McFarland, J. G., Wissert, M., Primiani, A., Hung, C., Bussel, J. B. (2007). Antepartum Treatment Without Early Cordocentesis for Standard-Risk Alloimmune Thrombocytopenia: A Randomized Controlled Trial. Obstet Gynecol 110: 249-255 [Abstract] [Full Text]  
• Berkowitz, R. L., Kolb, E. A., McFarland, J. G., Wissert, M., Primani, A., Lesser, M., Bussel, J. B. (2006). Parallel Randomized Trials of Risk-Based Therapy for Fetal Alloimmune Thrombocytopenia. Obstet Gynecol 107: 91-96 [Abstract] [Full Text]  
• OUWEHAND, W H, SMITH, G, RANASINGHE, E (2000). Management of severe alloimmune thrombocytopenia in the newborn. Arch. Dis. Child. Fetal Neonatal Ed. 82: 173F-175 [Full Text]  
• Bussel, J. B., Zabusky, M. R., Berkowitz, R. L., McFarland, J. G. (1997). Fetal Alloimmune Thrombocytopenia. NEJM 337: 22-26 [Abstract] [Full Text]  
• Dreyfus, M., Kaplan, C., Verdy, E., Schlegel, N., Durand-Zaleski, I., Tchernia, G., the Immune Thrombocytopenia Working Group, (1997). Frequency of Immune Thrombocytopenia in Newborns: A Prospective Study. Blood 89: 4402-4406 [Abstract] [Full Text]